<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02346032</url>
  </required_header>
  <id_info>
    <org_study_id>2014-07-148</org_study_id>
    <nct_id>NCT02346032</nct_id>
  </id_info>
  <brief_title>Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma</brief_title>
  <official_title>Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II Study of Refametinib, a MEK inhibitor, as second-line treatment in advanced biliary&#xD;
      tract adenocarcinoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Refametinib will be administered orally at the starting dose of 50 mg twice daily on a&#xD;
      continuous daily dosing schedule.&#xD;
&#xD;
      Self-administration of refametinib tablets will take place on an outpatient basis. Patients&#xD;
      experiencing dose-limiting toxicity attributed to study medication should have at least&#xD;
      1-week treatment breaks inserted into the continuous daily dosing period as needed and/or may&#xD;
      be interrupted or reduced depending on individual tolerability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2015</start_date>
  <completion_date type="Actual">October 13, 2016</completion_date>
  <primary_completion_date type="Actual">September 30, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>12months</time_frame>
    <description>the rate of complete response and partial response among all evaluable patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events in each cycle were documented based on CTCAE v 4.03</measure>
    <time_frame>24months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>12months</time_frame>
    <description>median time from response to progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>6months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory correlative analysis</measure>
    <time_frame>15 days</time_frame>
    <description>KRAS/PIK3CA mutation testing using BEAMing assay will be planned</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>refametinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>refametinib medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>refametinib</intervention_name>
    <description>Refametinib will be administered orally at the starting dose of 50 mg twice daily on a continuous daily dosing schedule.</description>
    <arm_group_label>refametinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age ≥ 18&#xD;
&#xD;
          2. histologically or cytologically confirmed adenocarcinoma of biliary tract&#xD;
&#xD;
          3. unresectable or metastatic&#xD;
&#xD;
          4. ECOG performance status of 0~2&#xD;
&#xD;
          5. measurable lesion per RECIST 1.1 criteria&#xD;
&#xD;
          6. adequate marrow, hepatic, renal functions&#xD;
&#xD;
          7. normal range of cardiac function confirmed by echocardiogram within 1 year (LVEF ≥50)&#xD;
&#xD;
          8. Child-Pugh Class A in case of liver cirrhosis&#xD;
&#xD;
          9. One prior treatment of cytotoxic chemotherapy (including adjuvant treatment within 12&#xD;
             months)&#xD;
&#xD;
         10. Resolution of all acute toxic effects of any prior therapy to Common Toxicity Criteria&#xD;
             for Adverse Events (CTCAE 4.03) ≤ grade 1.&#xD;
&#xD;
         11. provision of a signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of cardiac disease&#xD;
&#xD;
          2. Ongoing infection &gt; Grade 2 according to NCI-CTCAE version 4.03. Hepatitis B is&#xD;
             allowed if no active replication (defined as abnormal ALT &gt;2xULN associated with HBV&#xD;
             DNA &gt;20,000 IU/mL) is present&#xD;
&#xD;
          3. Severe co-morbid illness and/or active infections including active hepatitis C and&#xD;
             human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          4. History of interstitial lung disease (ILD).&#xD;
&#xD;
          5. Any cancer curatively treated &lt; 3 years prior to study entry, except cervical&#xD;
             carcinoma in situ, treated basal cell carcinoma, and superficial bladder tumors&#xD;
             (Staging: Ta, Tis and T1).&#xD;
&#xD;
          6. Renal failure requiring hemo- or peritoneal dialysis.&#xD;
&#xD;
          7. Clinically significant GI bleeding (CTCAE 4.03 grade 3 or higher) within 30 days prior&#xD;
             to start of screening&#xD;
&#xD;
          8. Thrombotic or embolic events such as cerebrovascular accident (including transient&#xD;
             ischemic attacks) within 6 months prior to start of screening.&#xD;
&#xD;
          9. History of organ allograft, cornea transplantation will be allowed&#xD;
&#xD;
         10. Active CNS metastases not controllable with radiotherapy or corticosteroids&#xD;
&#xD;
         11. Visible retinal pathology as assessed by ophthalmologic exam that is considered a risk&#xD;
             factor for RVO or CSR.&#xD;
&#xD;
         12. Known history of hypersensitivity to study drugs&#xD;
&#xD;
         13. Any condition that was unstable or which could jeopardize the safety of the patient&#xD;
             and his/her compliance in the study&#xD;
&#xD;
         14. Non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
         15. Patients with seizure disorder requiring medication.&#xD;
&#xD;
         16. Use of strong inhibitors of CYP3A4 and strong inducers of CYP3A4 should be stopped 2&#xD;
             weeks before start of screening (see Appendix 1).&#xD;
&#xD;
         17. Acute steroid therapy or taper for any purpose (chronic steroid therapy is acceptable&#xD;
             provided that the dose is stable for 1 month before start of screening and&#xD;
             thereafter).&#xD;
&#xD;
         18. Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the patient's participation in the study or evaluation of the study results.&#xD;
&#xD;
         19. Pregnant or lactating women. Women of childbearing potential not employing adequate&#xD;
             contraception. Women of childbearing potential must have a negative serum pregnancy&#xD;
             test performed within 7 days prior to start of study treatment and a negative result&#xD;
             must be documented before first dose of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>January 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Ho Yeong Lim</investigator_full_name>
    <investigator_title>MD, Ph.D, Devision of hematology-oncology, Department of medicine</investigator_title>
  </responsible_party>
  <keyword>second line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

